Scarica l'app Stockscreener
11.93
2.29%
-0.28
Dopo l'orario di chiusura:
11.90
-0.03
-0.25%
Precedente Chiudi:
$12.21
Aprire:
$11.9
Volume 24 ore:
3.92M
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.67B
Reddito:
$67.67M
Utile/perdita netta:
$-412.69M
Rapporto P/E:
-3.1177
EPS:
-3.8266
Flusso di cassa netto:
$-395.87M
1 W Prestazione:
-5.91%
1M Prestazione:
-0.75%
6M Prestazione:
-11.43%
1 anno Prestazione:
+5.67%
Intervallo 1D:
$11.66
$11.96
Intervallo di 1 settimana:
$11.66
$12.96
Portata 52W:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.93 | 1.71B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - Moomoo
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Canada
Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria
Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView
Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci
Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com
Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Australia
NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits
Why is Intellia Therapeutics stock rallying today? - Investing.com
Intellia stock rises on FDA priority review (NTLA:NASDAQ) - Seeking Alpha
NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z Review - GuruFocus
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance
Intellia Therapeutics stock jumps on FDA priority review - Investing.com
If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics
FDA grants lonvo-z priority review - CRISPR Medicine News
8-K: Intellia Therapeutics | 8-K: Current report - Moomoo
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Eastern Progress
Intellia Therapeutics, Inc. | NTLA Stock Price & Real-time Quotes - finance.biggo.com
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Locks In $400 Million OrbiMed Loan Tied to HAE Drug Milestones - finance.biggo.com
Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In - Yahoo Finance
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Eastern Progress
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors? - Yahoo Finance
Intellia Therapeutics Secures Major Non-Dilutive Loan Financing - TipRanks
Intellia Therapeutics Secures Up to $400 Million Five-Year Secured Credit Facility From OrbiMed - TradingView
FDA decision could unlock more of Intellia (NASDAQ: NTLA) $400M loan - Stock Titan
41 new hires get Intellia stock awards that vest annually for 3 years - Stock Titan
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch - AllSci
Intellia Therapeutics, Inc. Secures Non-Dilutive Debt Facility With OrbiMed For Up To $400 Million - marketscreener.com
NTLA Looks 4.3% Undervalued on GF Value™ Amid Strategic $400M Lo - GuruFocus
Intellia Therapeutics Enters $400 Million OrbiMed Term Loan Facility - marketscreener.com
Intellia Therapeutics Secures Up to $400 Million OrbiMed Debt Facility - citybiz
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - The Manila Times
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):